Stock data
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX) reported revenue of US$490.73M and net income of -US$25.55M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$490.73M | — | -US$62.82M | -US$25.55M | — |
| 2024 | US$233.18M | — | -US$323.83M | -US$321.55M | — |
| 2023 | US$145.24M | — | -US$388.14M | -US$111.40M | — |
| 2022 | US$109.46M | — | -US$319.81M | -US$278.48M | — |
| 2021 | US$131.84M | — | -US$199.43M | -US$180.09M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$169.58M | -US$34.80M | — |
| 2026-03-31 | US$127.20M | -US$37.10M | — |
| 2025-12-31 | US$129.69M | US$2.73M | — |
| 2025-09-30 | US$164.86M | US$25.71M | — |
| 2025-06-30 | US$114.45M | -US$12.76M | — |
| 2025-03-31 | US$81.73M | -US$41.23M | — |
| 2024-12-31 | US$74.79M | -US$60.26M | — |
| 2024-09-30 | US$62.90M | -US$54.81M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.